---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Prevalence"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: Prevalence. Topics: Prevalence in U.S. adults: National Health Interview Survey 2023; Prevalence in U.S. adults by sex, race and ethnicity, and body mass index, 2023; Prevalence in U.S. adults 20 years or older; Prevalence in U.S. adults by race and ethnicity and over time, NHANES; 14 further topics. 18 evidence topics quoted from 12 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description/prevalence"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Prevalence

<a id="heading-2.2.1.2.2"></a>

## 2.2.1.2.2 Prevalence of Moderate-to-severe plaque psoriasis

<a id="topic-2.2.1.2.2-1"></a>

### Prevalence in U.S. adults: National Health Interview Survey 2023

> “In this study we investigate the prevalence of psoriasis in adults (aged 18 years and older) using the 2023 National Health Interview Survey database.”
> “Our study includes 29,486 participants, of which 942 subjects reported a history of psoriasis.”
> “On cross sectional analysis using the most recently available data, approximately 3.0% of individuals aged 18 years and older reported a history of psoriasis (Table I).”
> “approximately 7.9 million US adults had psoriasis in 2023.”

Source: [Smith et al. (2025)](https://www.jaad.org/article/S0190-9622%2824%2903365-6/fulltext)

<a id="topic-2.2.1.2.2-2"></a>

### Prevalence in U.S. adults by sex, race and ethnicity, and body mass index, 2023

> “The prevalence of psoriasis was similar between males (3.1%) and females (2.9%). Overall, psoriasis was more prevalent in non-Hispanic White individuals (3.8%), individuals with a body mass index (BMI) of 30 or higher (3.6%), and those with health insurance (3.1%) (Table I).”

Source: [Smith et al. (2025)](https://www.jaad.org/article/S0190-9622%2824%2903365-6/fulltext)

<a id="topic-2.2.1.2.2-3"></a>

### Prevalence in U.S. adults 20 years or older

> “Psoriasis prevalence among US adults 20 years or older was 3.0% (95% CI, 2.6%-3.4%).”
> “Based on the 2020 census data, psoriasis affects approximately 7.55 million US adults aged 20 years or older.”

Source: [Armstrong et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8246333/)

<a id="topic-2.2.1.2.2-4"></a>

### Prevalence in U.S. adults by race and ethnicity and over time, NHANES

> “Overall, White individuals reported the highest prevalence of psoriasis at 3.6% (95% CI, 2.9%-4.2%). The lowest psoriasis prevalence was found in Black individuals, with a prevalence of 1.5% (95% CI, 1.0%-2.0%).”
> “The prevalence of psoriasis among those aged 20 to 59 years within the 2011-2014 NHANES data was 2.9% (95% CI, 2.5%-3.4%). This most recent prevalence estimate was not statistically different from prevalence estimates from prior years of 2.9% (95% CI, 2.3%-3.5%) during the 2009-2010 NHANES cycle and 3.2% (95% CI, 2.2%-4.5%) from the 2003-2004 NHANES cycle (P = .84).”

Source: [Armstrong et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8246333/)

<a id="topic-2.2.1.2.2-5"></a>

### Prevalence trend in U.S. adults: NHANES and NHIS, 2003 to 2024

> “Data from the 2003-2006 and 2009-2014 National Health and Nutrition Examination Survey and the 2023-2024 National Health Interview Survey were analyzed.”
> “The total sample included 53,225 participants.”
> “No temporal trends in prevalence were found in any sociodemographic subgroup.”

Source: [Schneiderman and Derrick (2026)](https://pubmed.ncbi.nlm.nih.gov/42083649/)

<a id="topic-2.2.1.2.2-6"></a>

### Diagnosed and undiagnosed psoriasis in U.S. adults

> “The prevalence of diagnosed psoriasis was 3.15% (95% CI 2.18, 4.53), corresponding to 5 million adults. The prevalence of undiagnosed active psoriasis by conservative estimate was 0.4% (95% CI 0.19, 0.82) corresponding to approximately 600,000 US adults.”

Source: [Kurd and Gelfand (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4762027/)

<a id="topic-2.2.1.2.2-7"></a>

### Moderate-to-severe fraction: three or more palms of body surface area

> “In this study, we found that 21.5% of participants reported having moderate to severe psoriasis (≥3 palms of body surface area involvement).”
> “The majority of patients with psoriasis reported having little or no psoriasis at the time of the survey.”

Source: [Armstrong et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8246333/)

<a id="topic-2.2.1.2.2-8"></a>

### Reported severity: no or little, mild, and moderate or severe disease

> “Psoriasis severity was generally mild: 54.5% (95% CI=44.8, 63.9) reported no or little disease; 27.3% (95% CI=21.1, 34.6) reported mild disease; and 18.2% (95% CI=12.4, 25.9) reported moderate or severe disease.”

Source: [Helmick et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4653077/)

<a id="topic-2.2.1.2.2-9"></a>

### Moderate-to-severe fraction and number affected, ages 20 to 59

| Body surface area category | Proportion of psoriasis patients |
| --- | --- |
| Little or no psoriasis | “51.59%” |
| 1% to 2% | “31.68%” |
| 3% to 10% | “11.38%” |
| More than 10% | “5.25%” |

Source: [Kurd and Gelfand (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4762027/)

> “83.37% of psoriasis patients with a history of physician diagnosis had mild psoriasis (little/no to 1–2% BSA) while 16.63% had moderate to severe disease (3% or greater BSA).”
> “Furthermore, we estimate that 1.4 million patients age 20–59 have moderate to severe disease and that 2.1 million consider psoriasis to be a large problem in daily life.”

Source: [Kurd and Gelfand (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4762027/)

<a id="topic-2.2.1.2.2-10"></a>

### Psoriasis prevalence and severity distribution in the adult population

> “The median prevalence of psoriasis in the adult population using the Bayesian estimate was 3.0% (95% credibility interval, 2.7–3.3%), compared with the estimated mean prevalence of 3.4% (95% confidence interval, 2.2–4.9%). By EE, the estimated cumulative distribution of disease severity assessed by BSA suggests that approximately 50% of patients have a BSA of < 3% and 78% of patients have a BSA of < 10%, with only 2% having a BSA of > 50%.”
> “Based on EE, approximately 22% of the adult population with psoriasis has 10% or more of BSA involved.”

Source: [Papp et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8163919/)

<a id="topic-2.2.1.2.2-11"></a>

### Insured U.S. population with moderate-to-severe psoriasis and untreated share

> “There were an estimated 1.7 million insured US patients with moderate to severe psoriasis. Of these, 1 million (59%) were not treated for their condition in the preceding year.”
> “Assigning disease severity by treatment types, excluding patients with mild disease (4,065,721) and those prescribed treatment for a related inflammatory comorbidity (191,753), resulted in an estimated 1,700,266 insured patients with moderate to severe psoriasis in the 5-year analysis window (Fig. 4). Of these, 546,814 (32.2%) were diagnosed but not treated.”

Source: [Armstrong et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5336424/)

<a id="topic-2.2.1.2.2-12"></a>

### Treatment types received by insured U.S. patients with moderate-to-severe psoriasis

> “Furthermore, of the patients treated (lapsed + currently treated) in the prior year, 156,409 (22.5%), 222,657 (32.0%), 22,911 (3.3%), and 293,511 (42.2%) received a biologic, traditional oral systemic, phototherapy, or a topical treatment, respectively (Fig. 4).”
> “In conclusion, this large health-plan-claims-based study showed that 40.9% of 1.7 million eligible US patients were receiving therapy for moderate to severe psoriasis in the 12 months up to September 2012.”

Source: [Armstrong et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5336424/)

<a id="topic-2.2.1.2.2-13"></a>

### Claims-based prevalence and severity distribution

> “Based on several psoriasis identification algorithms, the claims-based prevalence for psoriasis in the United States ranged from 0.51% to 1.23%.”
> “Using this method, 70.9% of patients had mild disease and 27.3% had moderate to severe disease (Table 4).”

Source: [Takeshita et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4549797/)

<a id="topic-2.2.1.2.2-14"></a>

### Therapies received in the claims analysis

> “Most patients had at least one claim for psoriasis therapy (83.5%), and 16.5% received no therapy. Topical therapies were used by 76.6% (N=3,551), the majority of whom received topical corticosteroids (97.9%). Phototherapy was used by 7% (N=324). Oral systemic medications were used by 14.3% (N=664), the majority of whom received methotrexate (85.7%).”

Source: [Takeshita et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4549797/)

<a id="topic-2.2.1.2.2-15"></a>

### Prevalence, severity at its worst, and undertreatment

> “The prevalence of psoriasis/PsA ranged from 1.4% to 3.3%; 79% had psoriasis alone and 21% had PsA. When rating disease severity at its worst, 27% (psoriasis) and 53% (PsA ± psoriasis) of patients rated it as severe.”
> “Of psoriasis patients, 45% had not seen a physician in a year; >80% of psoriasis patients with ≥ 4 palms body surface area and 59% of PsA patients were receiving no treatment or topical treatment only.”

Source: [Lebwohl et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24576585/)

<a id="topic-2.2.1.2.2-16"></a>

### Regional prevalence, including high income North America

> “The prevalence of psoriasis varied from 0.14% (95% uncertainty interval 0.05% to 0.40%) in east Asia to 1.99% (0.64% to 6.60%) in Australasia.”
> “Other regions with an occurrence of the disease above 1% were western Europe (1.92%, 1.07% to 3.46%), central Europe (1.83%, 0.62% to 5.32%), high income North America (1.50%, 0.63% to 3.60%)”

Source: [Parisi et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7254147/)

<a id="topic-2.2.1.2.2-17"></a>

### Global prevalent cases, Global Burden of Disease Study 2021

> “In 2021, the global prevalence number of people with psoriasis reached 42.98 million cases (95% CI: 41.65~44.31 million), representing an increase of approximately 86.4% compared to the number of cases in 1990.”

Source: [Gu et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12744867/)

<a id="topic-2.2.1.2.2-18"></a>

### Worldwide number of people with psoriasis

> “Approximately 125 million people worldwide have psoriasis.”

Source: [Armstrong and Read (2020b)](https://pubmed.ncbi.nlm.nih.gov/32427307/)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
